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Orogenital transmission is often suspected but rarely proven 
(1). In our study, use of whole-genome sequencing strongly 
supported the hypothesis that the oropharyngeal carriage of 
N. meningitidis by the man who performed oral sex was the 
source of the urethritis. Moreover, whole-genome sequenc-
ing showed that the strains belonged to the ST11 clonal 
complex. Several studies reported nongonococcal urethritis 
caused by N. meningitidis ST11 in Japan and the United 
States (1,6,7). These worldwide descriptions suggest that 
N. meningitidis S11 might represent an emerging urethro-
tropic clade.
This case is notable because the patient had highly 
symptomatic urethritis without risky sexual behavior. In 
fact, he reported that he and his only sexual partner had not 
had sex with others before they met.
Since 2010, several clusters of serogroup C invasive 
meningococcal disease have been reported among men who 
have sex with men, and sexual transmission is suspected to 
be involved (8–10). These infections led to an extension of 
the meningococcal vaccine recommendations to men who 
have sex with men who are engaged in risky behavior in 
some outbreaks areas. Our case highlights that sexual trans-
mission of N. meningitidis should be considered for all men.
Finally, although systematically collected information 
is limited, meningococcal urogenital infections are poten-
tially increasing and raising public health concerns. These 
infections need to be monitored, and bacteriological cul-
ture of purulent exudate should always be considered when 
available. Also, because fidelity might be contested be-
tween partners when a sexually transmitted disease is being 
diagnosed, identification of meningococcal urethritis and its 
transmission might have a strong psychological effect on 
the couple.
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We investigated azole resistance in Aspergillus fumigatus 
in a tertiary reference hospital in the Netherlands during 
1994–2016. The 5-year patient-adjusted proportion of re-
sistance increased from 0.79% for 1996–2001 to 4.25% 
for 2002–2006, 7.17% for 2007–2011, and 7.04% for 
2012–2016. However, we observed substantial variation 
between years.
Azole resistance is increasingly reported in Aspergillus fumigatus and is now found all around the world (1). 
Most studies have investigated the presence of resistance in 
environmental or clinical samples over a limited time, but 
longitudinal resistance studies are lacking. It is important 
to determine if azole resistance frequency shows increas-
ing trends over time and if the distribution of resistance 
mutations changes over time. We have previously reported 
the emergence of azole resistance from 1994–2007 for the 
Radboud University Medical Center (RUMC) in Nijmegen, 
the Netherlands (2). Here, we describe trends in resistance 
frequency and distributions of mutations over a 23-year pe-
riod, from 1994 through 2016.
All clinical A. fumigatus isolates cultured at RUMC are 
screened for azole resistance. Before 2009, isolates were 
screened using an agar-slant supplemented with 4 mg/L 
itraconazole (2). During 2009–2011 a 4-well plate was 
developed containing itraconazole (4 mg/L), voriconazole 
(1 mg/L), posaconazole (0.5 mg/L), and a growth control. 
Since 2012, we have used a commercial agar-based screen-
ing system (VIPcheck, http://www.vipcheck.nl) containing 
2 mg/L of voriconazole (3,4). We performed EUCAST sus-
ceptibility testing (http://www.eucast.org) and sequencing 
of the cyp51A gene and promoter on isolates that grew on 
azole-containing wells (2).
We calculated the resistance frequency of azole-resis-
tant A. fumigatus isolates for each year, using the number 
of cultured isolates as denominator. Furthermore, we cal-
culated the patient-adjusted proportion of resistance for 
each year and for each 5-year period, using the number 
of patients with a resistant isolate as numerator and of 
culture-positive patients as denominator. We determined 
by χ2 test whether trends of resistance frequency were 
statistically significant (p<0.05). When 2 different resis-
tance mechanisms were recovered from a single patient, 
we counted the patient once for determining the resistance 
proportion but used both isolates to determine the resis-
tance frequency.
Over the 23-year period, 4,268 A. fumigatus isolates 
were cultured from 2,051 patients, a resistance frequency 
of 4.2% (179/4,268 isolates). Azole-resistant A. fumigatus 
was found in 109/2,051 (5.3%) culture-positive patients 
(Figure, panel A). The patient-adjusted resistance propor-
tion increased from 0% in 1997 to 9.5% in 2016 (Figure, 
panel B). The increase of resistance was not statistically 
significant when the proportion of resistance for each con-
secutive year was analyzed. However, the 5-year propor-
tion of resistance increased from 0.79% for 1996–2001 to 
4.25% for 2002–2006, 7.17% for 2007–2011, and 7.04% 
for 2012–2016 (Figure, panel A). The increases in resis-
tance for 2002–2006 compared with 1996–2001 and for 
2007–2011 compared with 2002–2006 were statistically 
significant (p<0.05) (Figure, panel B). 
TR34/L98H was the most prevalent resistance mutation 
over the 23-year period; it was present in 77/109 (70.6%) 
patients with drug-resistant A. fumigatus (Figure, panel C). 
TR46/Y121F/T289A was found in 2 patients in 2010, 1 in 
2011, and 1 in 2012 but only twice during 2013–2016. In 
recent years, resistant phenotypes without Cyp51A muta-
tions were encountered more frequently than phenotypes 
with the mutation (Figure 1, panel C).
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Figure. Trends in azole resistance in Aspergillus fumigatus, the 
Netherlands, 1994–2016. A) Resistance frequency by number 
of total cultured A. fumigatus isolates and percentage of azole-
resistant isolates. B) Patient-adjusted proportion of resistance. 
Thick black horizontal bars indicate 5-year patient-adjusted 
proportion of resistance. p<0.05. C) Resistance mechanisms in 
azole-resistant A. fumigatus.
We observed an increasing trend in azole resistance 
prevalence in clinical A. fumigatus isolates until 2011, using 
number of patients with a positive culture as denominator. 
After 2011, the 5-year proportion of resistance remained 
stable. The advantages and disadvantages of different ap-
proaches of reporting resistance frequency remain under 
debate (5). Experts have recommended 10% resistance rate 
as the threshold for reconsideration of primary antifungal 
therapy (6), which indicates a need for consensus in how to 
determine resistance rates (5).
Although we found a substantial increase in azole 
resistance frequency over time, our study showed varia-
tion between consecutive years. Therefore, analysis of 
culture-positive patients over multiple years is required 
to determine local resistance epidemiology. Furthermore, 
resistance rates calculated using Aspergillus disease as de-
nominator provide more information to support changes in 
empiric treatment decisions, but the low number of culture-
positive patients in risk groups makes it difficult to obtain 
accurate estimates.
Various factors might have caused bias over the long 
period. The method of resistance detection changed from 
an agar-slant containing itraconazole to a system that con-
tained 3 azoles. Voriconazole- or posaconazole-resistant 
isolates with low itraconazole MICs may have been ini-
tially missed, but this phenotype is very uncommon (7). 
Other factors include increased awareness of resistance, 
the policy to screen multiple A. fumigatus colonies after 
observation of patients with mixed azole-susceptible and 
azole-resistant infection (8), and local changes in aspergil-
lus disease risk groups.
Resistance was dominated by environmental resis-
tance mutations TR34/L98H and TR46/Y121F/T289A, al-
though the number of patients with TR46/Y121F/T289A 
decreased in recent years. Furthermore, in the last 5 years, 
≈15% of resistant isolates harbored a wild-type Cyp51A 
gene, suggesting that other resistance mechanisms may be 
emerging. Because commercial PCR tests detect only re-
sistance mechanisms with TR34 (9) or TR34 and TR46 (10), 
our observation is relevant for using these assays in culture-
negative patients.
In summary, our study indicates an increasing azole re-
sistance trend in clinical A. fumigatus isolates in the Nether-
lands. Furthermore, our results highlight difficulties encoun-
tered in establishing local epidemiology of this resistance.
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